A new way to classify tuberculosis (TB) that aims to improve focus on the early stages of the disease has been presented by an international team involving researchers at UCL (University College ...

TMC207 is a first-in-class anti-TB diarylquinoline (also named R207910 or the 'J' compound) with activity against drug-sensitive and drug-resistant TB. TMC207 inhibits the proton pump of mycobacterial ...

A new way to classify tuberculosis (TB) that aims to improve focus on the early stages of the disease has been presented by an international team involving researchers at UCL. The new framework, ...

Recent Updates in Basic Research, Drug Discovery and Treatment - Volume II", we are pleased to announce the launch ...

Researchers from the University of Sydney and the Centenary Institute have discovered how a promising class of experimental antibiotics disrupts the bacterium that causes tuberculosis (TB), paving the ...

GSK announced in a press release on 14 November 2022 the positive results of its open-label phase 2a trial of GSK30336656, a first-in-class drug for the treatment of tuberculosis. The molecule ...

In 2020, more than 1.5 million people around the world died of tuberculosis, marking the first time in more than a decade that annual TB deaths had increased and demonstrating the global need for ...

Researchers have found that approved drugs that were originally shown to normalize blood vessels surrounding tumors (to improve drug delivery to cancer cells) can enhance the delivery of ...

BioVersys and partners publish in the prestigious journal of Nature Communications pre-clinical development data of AlpE (alpibectir and ethionamide), an innovative drug combination that overcomes ...